Memphasys (ASX:MEM) Short-Term Debt: A$4.11 Mil (As of Dec. 2025)


What is Memphasys Short-Term Debt?

Memphasys ASX:MEM -12.50% Short-Term Debt is A$4.11 Mil as of Dec. 2025. The stock has 6 warning signs investors should review.

Memphasys's Short-Term Debt for the quarter that ended in Dec. 2025 was A$4.11 Mil.

Memphasys's quarterly Short-Term Debt increased from Dec. 2024 (A$3.99 Mil) to Jun. 2025 (A$4.87 Mil) but then declined from Jun. 2025 (A$4.87 Mil) to Dec. 2025 (A$4.11 Mil).

Memphasys's annual Short-Term Debt declined from Jun. 2023 (A$4.55 Mil) to Jun. 2024 (A$4.41 Mil) but then increased from Jun. 2024 (A$4.41 Mil) to Jun. 2025 (A$4.87 Mil).

Memphasys Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Memphasys Short-Term Debt Related Terms

Memphasys Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Memphasys's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Memphasys Short-Term Debt Chart

Memphasys Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.18 3.56 4.55 4.41 4.87

Memphasys Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.89 4.41 3.99 4.87 4.11
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of A$4.11 Mil mean?
Memphasys (ASX:MEM) has a Short-Term Debt of A$4.11 Mil as of Dec. 2025.
Is Memphasys' Short-Term Debt too high?
Memphasys' current Short-Term Debt is A$4.11 Mil.
How does Memphasys' Short-Term Debt compare to ABT and SYK?
Memphasys' Short-Term Debt of A$4.11 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Medical Devices & Instruments company?
A good Short-Term Debt depends on the Medical Devices & Instruments industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Memphasys's current Short-Term Debt is A$4.11 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Memphasys stock overvalued right now?
Memphasys (ASX:MEM) has a current Short-Term Debt of A$4.11 Mil. The current Short-Term Debt is A$4.11 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Memphasys (ASX:MEM), the current Short-Term Debt is A$4.11 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Memphasys Business Description

Other Exchanges IG7:Germany
Address 34-36 Richmond Road, Level 1, Homebush West, Sydney, NSW, AUS, 2140
Memphasys Ltd is an Australian reproductive biotechnology company developing and commercializing novel reproduction and fertility solutions for humans and animals. The products in its development pipeline include a range of devices, media, and in vitro diagnostic solutions. The company is currently focused on the commercialisation of its patented Felix System, a novel bio-separation technology for assisted reproduction, designed to revolutionise sperm separation in assisted reproductive technology (ART) by providing a rapid, gentle, and automated process. The group has only one operating segment, being Reproductive Technologies, the assets and liabilities of which are located in Australia.